Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study

Authors

Roger J. Packer, George Washington UniversityFollow
Brian R. Rood, George Washington UniversityFollow
David Turner, St. Jude Children's Research Hospital, Memphis, TN
Clinton F. StewartFollow
Michael J. Fisher
Christopher Smith
Tina Young-Pouissant
Stewart Goldman
Rishi Lulla
Anu Banerjee
Alan Pollack
Larry E. Kun, St. Jude Children's Research Hospital, Memphis, TN
Arzu Onar-Thomas
Shengjie Wu, St. Jude Children's Research Hospital, Memphis, TN
James M. Boyett, University of Tennessee
Maryam Fouladi

Document Type

Journal Article

Publication Date

2014

Journal

Journal of Neuro-Oncology

Volume

Volume 121, Issue 1

Inclusive Pages

217-224

DOI

10.1007/s11060-014-1665-1

Keywords

Antineoplastic Agents--administration & dosage; Central Nervous System Neoplasms--drug therapy; Imidazoles--administration & dosage; Thiazoles--administration & dosage

Comments

PMCID: PMC4330963 [Available on 2016-01-01]

APA Citation

Packer, R.J., Rood, B.R., Turner, D.C., Stewart, C.F., Fisher, M. et al. (2014). Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. Journal of Neuro-Oncology, 121(1), 217-224.

Peer Reviewed

1